The race for the new generation of hepatitis C treatments
continues as Bristol-Myers Squibb (NYSE: BMY) takes first place in seeking
approval for a truly all-oral treatment independent of interferon and
ribavirin.
Gilead Sciences (NASDAQ: GILD)'s sofosbuvir and Johnson
& Johnson (NYSE: JNJ)'s simprevir both made significant progress toward FDA
approval by the end of this year. The oral agents have unfortunately only
undergone studies in conjunction with the injectable interferon, which is
associated with both its cumbersome method of delivery and unpleasant flu-like
side effects. Other agents have undergone studies in combination with
ribavirin, which is associated with side effects of anemia and rash. The
ultimate goal is to develop a stand-alone oral agent independent of both
interferon and ribavirin, achieve both ease of delivery and improved compliance
and more benign side effects. Read more.
No comments:
Post a Comment